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ABSTRACT 
TAK-063 is a selective phosphodiesterase 10A (PDE10A) inhibitor that produces potent 
antipsychotic-like and pro-cognitive effects at 0.3 mg/kg (26% PDE10A occupancy in rats) or 
higher in rodents through the balanced activation of the direct and indirect pathways of striatal 
medium spiny neurons. In this study, we evaluated the specific binding of TAK-063 using in 
vitro autoradiography and the modulation of brain activity using pharmacological magnetic 
resonance imaging (phMRI) and electroencephalography (EEG). [3H]TAK-063 significantly 
accumulated in the caudate—putamen, ventral pallidum, substantia nigra, hippocampus, and 
amygdala, but not in the frontal cortex, brainstem, or cerebellum in an autoradiography study 
using rat brain sections. [3H]TAK-063 accumulation in the caudate—putamen was more than 
eighteen-fold higher than that in the hippocampus and amygdala. TAK-063 at 0.3 mg/kg 
increased the blood oxygenation level-dependent (BOLD) signal in the striatum and amygdala, 
and decreased it in the frontal cortex in a phMRI study with anesthetized rats. TAK-063 at 0.3 
mg/kg significantly reduced the ketamine-induced increase in EEG gamma power both in 
awake and anesthetized rats. TAK-063 at 0.2 mg/kg (35% PDE10A occupancy in monkeys) 
also reduced the ketamine-induced increase in EEG gamma power in awake monkeys. In line 
with the EEG data, TAK-063 at 0.3 mg/kg reversed the ketamine-induced BOLD signal 
changes in the cortex, brainstem, and cerebellum in a phMRI study with anesthetized rats. 
These data suggest that TAK-063 at about 30% PDE10A occupancy modulates activities of 
multiple brain regions through activation of neuronal circuits in rats and monkeys. 
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Abbreviations 
Amy, amygdala; ARG, autoradiography; AUC, area under the curve; BOLD, blood 
oxygenation level-dependent; Bs, brainstem; cAMP, cyclic adenosine monophosphate; Cb, 
cerebellum; cGMP, cyclic guanosine monophosphate; CNS, central nervous system; CPu, 
caudate—putamen; EEG, electroencephalography; Fcx, frontal cortex; FFT, Fast Fourier 
Transformations; Hipp, hippocampus; ic, internal capsule; MSNs, medium spiny neurons; 
NMDA, N-methyl-D-aspartate; PDE10A, Phosphodiesterase 10A; phMRI, pharmacological 
magnetic resonance imaging; PSL, photostimulated luminescence; SN, substantia nigra; VP, 
ventral pallidum  
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Introduction 
The connectivity of the corticostriatal circuit enables sensory inputs to be associated with the 
output functions such as motor and cognitive responses (Shepherd, 2013). The circuit consists 
of a cortical and a striatal component (Hersch et al., 1995, Bolam et al., 2000), and the 
medium spiny neurons (MSNs) in the striatum are the principal cells that receive inputs from 
cortical components. MSNs project in two different directions, namely the direct and indirect 
pathways (Gerfen and Surmeier, 2011). These two pathways are considered to have a 
competing effect on the striatal outputs and on the consequent modulation of thalamic and 
cortical functions (Silkis, 2001). 
Phosphodiesterase 10A (PDE10A) is a dual-substrate enzyme that hydrolyzes both Cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) (Fujishige 
et al., 1999, Soderling et al., 1999). PDE10A is highly expressed in MSNs of the mammalian 
striatum (Soderling and Beavo, 2000, Seeger et al., 2003, Xie et al., 2006), and regulates the 
output function of both the direct and indirect pathways (Siuciak et al., 2006). Dysfunction of 
the corticostriatal circuit has been implicated in various central nervous system (CNS) 
disorders including schizophrenia; thus, pharmacological inhibition of PDE10A and the 
resulting activation of the corticostriatal circuit could be a promising therapeutic approach for 
these disorders (Kehler and Nielsen, 2011, Kehler, 2013). 
TAK-063 is a potent, selective, and orally active PDE10A inhibitor (Kunitomo et al., 2014, 
Harada et al., 2015). Similar to other PDE10A inhibitors such as MP-10 (Schmidt et al., 2008, 
Grauer et al., 2009), TAK-063 showed potent antipsychotic-like effects in some rodent models 
of schizophrenia such as MK-801-induced hyperactivity, and lower risks of side effects than 
that showed by the current antipsychotics (Suzuki et al., 2015). Interestingly, TAK-063, but 
not MP-10, showed potent antipsychotic-like effects in methamphetamine-induced 
hyperactivity and prepulse inhibition deficits in rodents. Characterization of underlying 
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mechanisms of action revealed that TAK-063 can induce more balanced activation of the 
direct and indirect pathways than MP-10 did via its faster off-rate from PDE10A (Suzuki et al., 
2016). In addition, TAK-063 enhanced various cognitive functions, such as recognition 
memory, attention, impulsivity, working memory, and executive function, in naïve rats or in 
the N-methyl-D-aspartate (NMDA) receptor antagonist-induced rodent models of 
schizophrenia (Shiraishi et al., 2016). Thus, it is plausible that TAK-063 can modulate the 
function of multiple brain regions through the augmentation of striatal outputs. 
In this study, we evaluated the detailed binding pattern of TAK-063 using in vitro 
autoradiography (ARG) with rat serial brain sections, and then investigated the effects of 
TAK-063 on brain activity by pharmacological magnetic resonance imaging (phMRI) in rats 
and electroencephalography (EEG) in rats and monkeys. EEG has a good temporal resolution 
and directly measures the neuronal activity although it has limited spatial resolution restricted 
to the cortical region close to the surface of the brain (Gloor, 1985). phMRI, on the other hand, 
has a whole brain coverage but suffers from limitation of low temporal resolution; the blood 
oxygenation level-dependent (BOLD) response in phMRI is only indirectly linked to a 
neuronal activity (Leslie and James, 2000). The three methods together therefore should be 
highly complementary and help to reveal a fuller picture of the effects of TAK-063 on the 
brain function. To gain a better insight into the pharmacological profile of TAK-063 as a drug 
for schizophrenia, we also investigated the effect of TAK-063 on the signal produced by 
ketamine, an NMDA receptor blocker, that is known to induce schizophrenia-like symptoms 
in multiple species (Littlewood et al., 2006b, Pinault, 2008, Hodkinson et al., 2012, Doyle et 
al., 2013, Gil-da-Costa et al., 2013). Herein we report preclinical evidence that TAK-063, by 
binding to PDE10A, can modulate the neuronal activity in multiple brain regions through 
activation of neuronal circuits. 
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Material and methods 
Animals 
A total of 158 rats and 6 monkeys were included in the experiment. Male Wistar (CLEA Japan, 
Inc., Tokyo, Japan) and Sprague Dawley (SD) rats (Charles River Laboratories Japan, Inc., 
Yokohama, Japan, and Charles River, UK) were kept under standard laboratory conditions 
(12:12 h light/dark cycle) with food and water available ad libitum. Female cynomolgus 
monkeys (Macaca fascicularis, Keari Co., Ltd., Osaka, Japan) were kept under standard 
laboratory conditions and fed once daily with water available ad libitum. The care and use of 
the animals and the experimental protocols were in accordance with the guideline of 
Institutional Animal Care and Use Committee (Takeda Pharmaceutical Company Limited., 
Pharmacology Research Laboratories, Kanagawa, Japan) and UK Animals (Scientific 
Procedures) Act of 1986 and the Ethical Review Panel of King’s College London.  
 
Chemicals and radioligand 
TAK-063 and MP-10 succinate were synthesized by Takeda Pharmaceutical Company 
Limited (Kanagawa, Japan) (Verhoest et al., 2009, Kunitomo et al., 2014). [3H]TAK-063 
(37.0 MBq/mL in ethanol) was synthesized by Sekisui Medical Co., Ltd. (Tokyo, Japan). The 
specific radioactivity and radiochemical purity of [3H]TAK-063 were 665 GBq/mmol and 
98.1%, respectively. Ketamine hydrochloride (Daiichi Sankyo Propharma Co., Ltd., Tokyo, 
Japan, or Tocris Bioscience, Abingdon, UK), (+)-MK-801 hydrogen maleate (Sigma-Aldrich, 
St. Louis, MO), propofol (Maruishi Pharmaceutical Co., Ltd., Osaka, Japan), and isoflurane 
(Abbott Laboratories, TX) were obtained commercially. TAK-063 was suspended in 0.5% 
(w/v) methylcellulose in distilled water for oral (p.o.) or 0.5% (w/v) methylcellulose in saline 
for intraperitoneal (i.p.) administration to rats. TAK-063 was dissolved in the following 
vehicle and administered intravenously (i.v.) to monkeys: 5% (v/v) N, N-dimethylacetamide, 
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10% (v/v) Ethanol, 30% (v/v) PEG-400, and 55% (w/v) Sulfobutylether-β-cyclodextrin. 
Ketamine was dissolved in saline and administered subcutaneously (s.c.) to rats or 
intramuscularly (i.m.) to monkeys. 
 
Regions of interest (ROI) of the brain 
ROI were set and abbreviated as follows by referring to the brain atlas (Paxinos and Watson, 
1997): frontal cortex (Fcx), caudate—putamen (CPu), ventral pallidum (VP), hippocampus 
(Hipp), internal capsule (ic), amygdala (Amy), substantia nigra (SN), brainstem (Bs), and 
cerebellum (Cb). 
 
In vitro ARG with rat brain sections 
A total of 4 male SD rats were included in the experiment. In vitro ARG was conducted as 
previously described (Harada et al., 2015). The brains of SD rats were frozen, and then 
sagittal or serial coronal brain sections at 10.5, 7.6, 5.3, 3.8, 0.4 mm posterior and 3.2 mm 
anterior to bregma were cut in a cryostat (Leica Microsystems, Wetzlar, Germany). After 
pre-incubation twice for 5 min in buffer (50 mM Tris-HCl pH 7.5, 1.7 mM EDTA, 6 mM 
MgCl2, 120 mM NaCl, and 0.1% BSA) at room temperature, the sections were incubated in 
binding buffer (50 mM Tris-HCl pH 7.5, 1.7 mM EDTA, 6 mM MgCl2, 120 mM NaCl, 0.1% 
BSA, and 0.03% Triton X-100) containing 20 nM [3H]TAK-063 for 60 min at room 
temperature. Adjacent sections were used for the blocking study by adding MP-10 (final 
concentration of 1 µM). The sections were washed twice for 5 min at 4°C in pre-incubation 
buffer, and then rapidly rinsed in ice-cold distilled water. The sections were dried under a 
stream of cool air, and were exposed to BAS IP TR 2040E imaging plates (GE Healthcare UK 
Ltd.) for 7 days. The imaging plates were analyzed using an image analyzer and software 
(FLA-7000 and Image Gauge, Fujifilm, Tokyo, Japan). Radioactivity in each ROI was 
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analyzed and represented as photostimulated luminescence (PSL) values (/mm2). The 
background was subtracted from the PSL values of each ROI, and the PSL values in each 
brain region were then averaged for each group. The PSL values in the absence and presence 
of 1 µM MP-10 were represented as total binding and blocked by MP-10, respectively. 
 
Measurement of cyclic nucleotides in the rat striatum 
A total of 32 male SD rats were included in the experiment. SD rats were sacrificed using an 
MMW-05 focused microwave irradiation system (Muromachi Kikai Co. Ltd., Tokyo, Japan) 
30 min after i.p. administration of TAK-063. Striatum tissues were isolated, sonicated in 0.5 N 
HCl, and clarified by centrifugation. cAMP and cGMP concentrations in the supernatants 
were measured using enzyme immunoassay kits (Cayman Chemical Company, Ann Arbor, 
MI). 
 
MK-801-induced hyperactivity in rats  
A total of 28 male SD rats were included in the experiment. Locomotor activity of the rats 
was measured using a SUPERMEX spontaneous motor analyzer (Muromachi Kikai Co., 
Tokyo, Japan). SD rats were placed in locomotor chambers (length × width × height: 24 × 37 
× 30 cm) for more than 60 min for habituation. Thereafter, rats were removed from each 
chamber and treated with either vehicle or TAK-063 (i.p.) and then quickly returned to the 
chamber. Rats were again removed from the chambers 30 min after administration of 
TAK-063 and treated with either vehicle (saline) or MK-801 (0.3 mg/kg as hydrogen maleate 
salt, s.c.) and then quickly transferred to the test chamber. Activity counts were recorded in 
successive 1-min bins, and then cumulative counts during 120 min after psychostimulant 
administration were calculated. 
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EEG in awake rats 
A total of 40 male Wistar rats were included in the experiment. Under anesthetic control, 
stainless steel screw electrodes were stereotaxically positioned on the prefrontal cortex (3 mm 
anterior and 2.5 mm lateral to bregma) with care not to rupture the dura. Reference electrode 
was positioned on the cerebellum. Rats were allowed to recover for a minimum of one week 
before electroencephalography (EEG) recording. EEG was recorded in awake, freely-moving 
conditions. After 5 min of baseline recording, rats were treated with vehicle, TAK-063 
(0.03–3 mg/kg p.o.), or MP-10 (0.3–30 mg/kg p.o.). Ketamine (10 mg/kg s.c.) was 
administered 90 (for TAK-063 study) or 60 min (for MP-10 study) min after the drug (p.o.) 
administration. EEG was recorded for more than 150 min in total. EEG signals were filtered 
at 0.1–1 kHz, amplified using an AC amplifier (BBA-2208; Biotex Ltd., Kyoto, Japan), and 
digitized at 500 Hz using a MICRO3 interface system (Cambridge Electronic Design Ltd., 
Cambridge, UK). Spike 2 software (Cambridge Electronic Design Ltd., Cambridge, UK) was 
used to conduct Fast Fourier Transformations (FFT) analysis and to calculate the total power 
in the gamma (30–80 Hz) frequency. FFT values of the noise-free 32-sec epoch were used as 
the representative value for 5 min bin. The gamma power of the each 5 min bin was 
normalized to the gamma power during baseline recording, and then area under the curve 
(AUC) for resting (0 to 90 or 60 min before the ketamine challenge) and ketamine-induced 
activated (0 to 60 min after the ketamine challenge) states were calculated for the statistical 
data analysis. 
 
EEG in anesthetized rats 
This experiment was conducted at King’s College London. A total of 22 male SD rats were 
included in the experiment. Under anesthetic control, monopolar surface electrodes were 
stereotaxically positioned on the parietal cortex (1 mm posterior and 2 mm lateral to bregma) 
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with care not to rupture the dura. Reference electrode was positioned on the nasal bone. The 
rats were allowed to recover for a minimum of one week before EEG recordings. EEG was 
recorded under isoflurane anesthesia (1.5% in air/oxygen mixture 1.0/0.4 L/min). After 5 min 
of baseline recording, the rats were treated with vehicle or TAK-063 (0.3–3 mg/kg i.p.). 
Ketamine (10 mg/kg s.c.) was administered 30 min after the drug (i.p.) administration. EEG 
was recorded for more than 90 min in total. EEG signals were filtered at 0.1–140 Hz, 
amplified, and digitized online using Biopac MP100 system (BIOPAC Systems, Inc., Goleta, 
CA, USA). Matlab function was used to perform a power spectral analysis of EEG recording 
and to calculate energy in gamma (30–80 Hz) frequency range for every minute of the 
recording. The gamma power of the each 1 min bin was normalized to the gamma power 
during baseline recording, and then AUC for resting (0 to 15 min before the ketamine 
challenge) and ketamine-induced activated (10 to 25 min after the ketamine challenge) states 
were calculated for the statistical data analysis. 
 
EEG in awake monkeys 
A total of 6 female Cynomolgus monkeys were included in the experiment. Under anesthesia 
with propofol (60 mg/h), stainless screw electrodes were positioned on the left and right 
frontal, parietal, and occipital cortex, with care not to rupture the dura. The monkeys were 
allowed to recover for a minimum of one month before EEG recording. For EEG recording in 
awake states, monkeys were placed on a monkey chair. A catheter was inserted into brachial 
veins for continuous drug infusion. After 5 min of baseline recording and 15 min of 
non-treatment phase, monkeys were treated with vehicle or TAK-063 (0.2 and 0.8 mg/kg/h for 
30 min) by intravenous infusion. Ketamine (1 mg/kg i.m.) was administered 10 min after the 
initiation of drug infusion. EEG was recorded for more than 60 min in total. Experiment was 
repeated using the same animal with an interval of more than 1 week. EEG signals were 
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filtered (0.5–100 Hz), amplified, digitized online, and EEG montage for FFT analysis was 
obtained using frontal and occipital cortex electrodes (EE5518, NEC Medical Systems, Tokyo, 
Japan). SleepSign program (Kissei Comtec, Nagano, Japan) was used to conduct FFT analysis 
and to calculate the total power in the gamma (30–80 Hz) frequency. The gamma power of the 
each 5 min bin was normalized to the gamma power during baseline recording, and then AUC 
for resting (0 to 10 min before the ketamine challenge) and ketamine-induced activated (0 to 
20 min after the ketamine challenge) states were calculated for the statistical data analysis. 
 
Statistical analysis of EEG and ARG data 
Data are presented as mean+standard error of the mean (SEM). Pairwise differences were 
analyzed using Aspin-Welch’s t-test. Dose-related effects were analyzed using Bartlett’s test, 
which was used for testing the homogeneity of variances, followed by two-tailed Williams’ 
test (for parametric data, P>0.05 by Bartlett’s test) or two-tailed Shirley-Williams test (for 
non-parametric data, P≤0.05 by Bartlett’s test). Data were analyzed using EXSUS (Ver.8.0.0, 
CAC EXICARE Corporation, Tokyo, Japan) and statistical significance was set at P≤0.05. 
 
phMRI in rats 
This experiment was conducted at King’s College London. A total of 32 male SD rats were 
included in the experiment. Pharmacological MRI was conducted on a 7 Tesla (T) horizontal 
bore MR scanner (Agilent, USA) using a birdcage quadrature radiofrequency coil (Magnetic 
Resonance Laboratories, UK). SD rats were anesthetized with isoflurane and transferred to 
the scanner and secured in a stereotaxic head frame. Subcutaneous and intraperitoneal 
cannulas were implanted for drug administration, and probes were attached for monitoring 
oxygen saturation, heart rate (Nonin, USA), and respiratory rate (Biopac Systems Inc, USA). 
A rectal probe coupled to a thermostat-controlled heating blanket was used to maintain the 
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body temperature at 37±1ºC (Harvard Apparatus, USA). Anesthesia was maintained at 
1.5-1.8% isoflurane (in oxygen/air 1:9, a flow of 1 L/min) throughout the experiment. Fast 
spin echo structural MR images were first acquired (TR=4000 ms; effective TE=60 ms, FOV 
3.2 x 3.2 cm, matrix 128 x 128 x 24 voxels, 1 mm thick contiguous slices in 8 min 40 sec). 
The BOLD sensitive gradient echo MR sequence consisted of 56 x 32” whole brain scans 
obtained before TAK-063, followed by another 56 scans before ketamine and 56 scans after 
ketamine/vehicle injection, yielding a total imaging time for 168 brain volumes of ca. 90 
minutes. The imaging parameters were TR=500 ms, multi TE of 5, 10 and 15 ms (mean TE 
was analyzed), flip angle 30º, FOV 3.2 x 3.2 cm, matrix 64 x 64 x 24 voxels, 1 mm thick 
contiguous slices.  
Images were converted from native format to Analyze format using a locally written Matlab 
script. All preprocessing and statistical image analysis was performed by SPM8 software 
(UCL, London). Intra-session movement correction (6-parameter, rigid body spatial 
transformation) of the time series was performed using the first image of the series 
(co-registered to anatomical scan) as reference. A brain mask was created using the software 
Jim (version 5.0_10, Xinapse Systems Inc., UK), and applied to all the realigned volumes of 
the time series. Resulting images contained only brain tissue. Images were then spatially 
normalized to a local rat brain template. Individual animals were analyzed using a General 
Linear Model approach, which measures the correlation between the signal intensity changes 
and hypothetical regressors. Regressor was derived from the EEG bench experiment and 
consisted of 140 zeroes (0’s), followed by 28 ones (1’s). The level of statistical significance 
was set at P<0.05 (uncorrected). A second-level (random effects) group analysis was then 
performed, using the contrast images generated in the first-level analysis. To highlight the 
effect of the treatments, statistical parametric maps (SPMs) figures were produced with the 
level of statistical significance set at P<0.05 (uncorrected).  
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Results 
TAK-063 highly accumulated in striatal complex in rat brain sections and modified the 
phMRI-BOLD signal in multiple brain regions in anesthetized rats 
We previously reported that TAK-063 specifically bound to PDE10A in the rodent brain 
sections (Harada et al., 2015). Thus, ARG study with [3H]TAK-063 is a sensitive way to 
understand not only binding pattern of TAK-063 but also the distribution of PDE10A protein 
in rodent brain. To obtain a more precise binding pattern of TAK-063 and to determine how 
this consequently affects neuronal activity in various rat brain regions, we performed a 
detailed in vitro ARG using [3H]TAK-063 and serial coronal brain slices at 10.5, 7.6, 5.3, 3.8, 
0.4 mm posterior and 3.2 mm anterior from Bregma (Figure 1A). [3H]TAK-063 radioactivity 
was measured in several brain regions in the presence or absence of 1 µM of MP-10, a potent 
PDE10A inhibitor, and was represented as a PSL value (/mm2); the PSL values in the presence 
of 1 µM of MP-10 were considered as background (Figure 1B). In line with our previous 
results, [3H]TAK-063 highly accumulated in the CPu and SN where PDE10A is highly 
expressed (Figure 1A, 1B, CPu: df (degrees of freedom) = 3.06, t = 7.83, P≤0.05; SN: df = 
3.29, t = 15.12, P≤0.05, Aspin-Welch’s test), and a weaker but significant accumulation of 
[3H]TAK-063 was detected in the Hipp (Figure 1B, df = 6.00, t = 2.45, P≤0.05, Aspin-Welch’s 
t-test). Moreover, in this study, [3H]TAK-063 also highly accumulated in the VP and ic, and a 
weaker but significant accumulation was detected in the Amy (Figure 1A, 1B, VP: df = 3.19, t 
= 17.15, P≤0.05; i.c.: df = 3.96, t = 15.35, P≤0.05; Amy: df = 3.75, t = 4.26, P≤0.05, 
Aspin-Welch’s t-test). The specific PSL value in the CPu was more than eighteen-fold higher 
than in the Hipp and Amy (CPu 221.2±25.4, Hipp 7.1±1.6, Amy 12.1±2.9). 
In our previous studies with rodent models of schizophrenia, TAK-063 was efficacious for 
psychosis—like symptoms and cognitive deficits at 0.3 mg/kg p.o. (26% PDE10A occupancy), 
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and produced a weak cataleptic response at 3 mg/kg p.o. (77% PDE10A occupancy) (Suzuki 
et al., 2015, Shiraishi et al., 2016). Oral administration of TAK-063 was not available for 
experiments performed under anesthesia. TAK-063 with i.p. administration produced 
up-regulation of striatal cyclic nucleotides (Figure 1C and D, cAMP: P>0.05 by Bartlett’s test, 
0.3 mg/kg, df = 28, t = 2.51, P≤0.05, Williams’ test; cGMP: P>0.05 by Bartlett’s test, 0.1 
mg/kg, df = 28, t = 2.17, P≤0.05; 0.3 mg/kg, df = 28, Z = 2.52, P≤0.05, Williams’ test) and 
suppression of MK-801-induced hyperactivity (Figure 1E, P≤0.05 by Bartlett’s test, 0.1 
mg/kg, df = 20, t = 2.70, P≤0.05; 0.3 mg/kg, df = 20, t = 3.67, P≤0.05, Shirley-Williams test ) 
in rats. Given that the dose response effects of TAK-063 were similar between i.p. and p.o. 
administration (Suzuki et al., 2015), we chose to investigate the dose of 0.3 mg/kg i.p. as an 
efficacious dosage for our imaging studies. 
In the rat phMRI study observing the pattern of the changes of the neuronal activity in a brain 
coronal plane, intraperitoneal administration of TAK-063 at 0.3 mg/kg induced significant 
increases in BOLD signal in the CPu and Amy, whereas it decreased BOLD signal in the Fcx 
under isoflurane anesthesia (Figure 1F). TAK-063 at 3 mg/kg i.p. induced more localized and 
bilateral increases in BOLD signal in the CPu and Amy, and prominent negative BOLD signal 
in the Bs and Cb (Figure 1G). The phMRI data in the sagittal plane showed that TAK-063 at 
0.3 and 3 mg/kg i.p. produced significant increases in BOLD signal in the CPu and SN 
corresponding with the high specific binding of [3H]TAK-063 observed in the ARG with rat 
sagittal brain sections. On the other hand, a negative BOLD signal was observed in brain 
areas such as the Fcx and Bs where the specific binding of [3H]TAK-063 was not observed in 
the ARG study (Figure 1H). These results suggest that TAK-063 modifies the neuronal 
activity in brain regions beyond the localization of PDE10A in the rat brain. 
 
TAK-063 reduced both the resting and ketamine-induced cortical EEG gamma power in 
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awake rats 
The in vivo phMRI results suggested that TAK-063 modifies neuronal activity in the cortex; 
thus, we assessed the effect on cortical EEG gamma power, a possible indicator of activation 
of neuronal assembly (Niessing et al., 2005), in awake rats. Because ketamine is reported to 
induce aberrant cortical activation that is similar to that associated with schizophrenia 
(Baldeweg et al., 1998, Lee et al., 2008) and TAK-063 showed antipsychotic-like and 
pro-cognitive effects in NMDA antagonist-induced rodent models of schizophrenia (Suzuki et 
al., 2015, Shiraishi et al., 2016), we used ketamine here to assess the effect of TAK-063. 
In awake rats, oral administration of TAK-063 reduced the resting gamma power measured 
before ketamine challenge (Figure 2A), and the AUC analysis showed a significant reduction 
of the resting gamma power at 3 mg/kg p.o., but not at 0.3 mg/kg p.o. or lower (Figure 2B, 
P>0.05 by Bartlett’s test, df = 12, t = 4.55, P≤0.05, Williams’ test). The ketamine challenge 
(10 mg/kg s.c.) increased the gamma power in the vehicle group (activated states, Figure 2A), 
and this ketamine-induced increase in gamma power was reduced by TAK-063; the AUC 
analysis confirmed that ketamine significantly increased the gamma power (df = 4.54, t = 8.82, 
P≤0.05, Aspin-Welch’s t-test) and that the ketamine-induced increase in gamma power was 
significantly suppressed by TAK-063 at both 0.3 and 3 mg/kg p.o. (Figure 2C, P>0.05 by 
Bartlett’s test, 0.3 mg/kg, df = 12, t = 5.23, P≤0.05; 3 mg/kg, df = 12, t = 4.57, P≤0.05, 
Williams’ test ). These data suggest that TAK-063 at 0.3 mg/kg p.o. and higher suppresses the 
ketamine-induced aberrant change in cortical activity measured by EEG. 
In our previous study, TAK-063, but not MP-10, produced potent antipsychotic-like effects in 
methamphetamine-induced hyperactivity and prepulse inhibition deficits in rodents (Suzuki et 
al., 2016). To gain some insight into the difference between TAK-063 and MP-10, we 
assessed the effect of MP-10 on cortical EEG gamma power. Similar to TAK-063, oral 
administration of MP-10 reduced the resting gamma power measured before ketamine 
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challenge (Figure 2D), and the AUC analysis showed a significant reduction of the resting 
gamma power at 30 mg/kg p.o. (Figure 2E, P>0.05 by Bartlett’s test, df = 12, t = 3.74, P≤0.05, 
Williams’ test). On the other hand, MP-10 at dose up to 30 mg/kg p.o. did not significantly 
reduce the ketamine-induced increase in gamma power (Figure 2F). 
 
TAK-063 reduced the ketamine-induced, but not resting, cortical EEG gamma power in 
awake monkeys 
To understand the possible species differences in TAK-063-induced EEG changes, we next 
examined the effect of TAK-063 on cortical EEG before and after ketamine challenge in 
monkeys. In our previous monkey study, intravenous administration of TAK-063 at 0.2 and 
0.8 mg/kg produced 35% and 73% PDE10A occupancy, respectively (Takano et al., 2015, 
Takano et al., 2016). In rodents, TAK-063 at around 30% occupancy produced potent 
antipsychotic-like and pro-cognitive effects (Suzuki et al., 2015, Shiraishi et al., 2016), thus 
0.2 mg/kg i.v. was selected as a possible efficacious dosage in monkeys. In awake monkeys, 
TAK-063 at 0.2 and 0.8 mg/kg i.v. did not affect the resting gamma power (Figure 3A, B). 
The ketamine challenge (1 mg/kg i.m.) acutely increased the gamma power and this was 
suppressed by TAK-063 (Figure 3A); the AUC analysis confirmed that ketamine significantly 
increased the gamma power (df =9.87, t = 8.05, P≤0.05, Aspin-Welch’s t-test) and that 
TAK-063 at both 0.2 and 0.8 mg/kg i.v. significantly reduced this increase (Figure 3C, P>0.05 
by Bartlett’s test, 0.2 mg/kg, df = 15, t = 3.68, P≤0.05; 0.8 mg/kg, df = 15, t = 5.85, P≤0.05, 
Williams’ test,). These data, together with the EEG data measured in rats (Figure 2), suggest 
that TAK-063 suppresses the ketamine-induced activation of cortical neurons at similar 
occupancy (~30%) in both rats and monkeys.  
 
Ketamine-induced increase in cortical gamma power and its reduction by TAK-063 in 
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rats were preserved under isoflurane anesthesia 
PhMRI study using rats should be performed under anesthesia because of the ethical 
requirements and the inability to keep the animals completely still and stress-free in the 
scanner. To further characterize the effect of TAK-063 on ketamine-induced cortical 
modulation using phMRI, we decided to investigate the effects of isoflurane anesthesia on the 
EEG parameters of interest. Because the experiment was conducted under anesthesia, 
TAK-063 was administered intraperitoneally. In isoflurane anesthetized rats, i.p. 
administration of TAK-063 continued to suppress the ketamine-induced (10 mg/kg s.c.) 
increases in gamma power without affecting the resting gamma power (Figure 4A, B). The 
AUC analysis confirmed that ketamine significantly increased the gamma power (df = 5.57, t 
= 4.40, P≤0.05, Aspin-Welch’s t-test) and that TAK-063 at 0.3 and 3 mg/kg i.p. significantly 
reduced this increase (Figure 4C, P>0.05 by Bartlett’s test, 0.3 mg/kg, df = 14, t = 2.43, 
P≤0.05; 3 mg/kg, df = 14, t = 3.70, P≤0.05, Williams’ test). Thus, isoflurane was selected as 
an anesthesia to further investigate the effects of TAK-063 on ketamine-induced cortical 
modulation by phMRI. 
 
TAK-063 reversed the ketamine-induced changes in phMRI-BOLD signals in multiple 
brain regions in rats 
The ketamine challenge (10 mg/kg s.c.) produced an increase in BOLD signal in many brain 
regions, including the cortex, CPu, Hipp, and Amy. Ketamine, on the contrary, decreased the 
signal in the Bs, Cb, and hypothalamus (Figure 5A, D). TAK-063 at 0.3 mg/kg i.p. suppressed 
the ketamine-induced increase in BOLD signal in the Hipp and cortical areas such as the 
cingulate (frontal) and retrosplenial (parietal) cortex. On the other hand, TAK-063 at 0.3 
mg/kg i.p. reversed the ketamine-induced decrease in BOLD signal in the Bs, Cb, and 
hypothalamus. In addition, TAK-063 at 0.3 mg/kg i.p. increased the signal in the thalamus and 
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hypothalamus and augmented the ketamine-induced increases in the CPu (Figure 5B, E). 
TAK-063 at 3 mg/kg i.p. suppressed the ketamine-induced cortical signals more strongly than 
at 0.3 mg/kg i.p., with a more robust and localized activation of the CPu and Amy. However, 
TAK-063 at 3 mg/kg i.p. did not change the activity in the thalamic and hypothalamic areas 
(Figure 5C, F). These data suggest that TAK-063 at the efficacious dosage modulates the 
ketamine-induced BOLD signal changes, while some of the effects disappear with 
overdosing. 
 
Discussion 
In our previous ARG study with brain sections of wild-type (WT) and PDE10A knock-out 
(KO) mice, [3H]TAK-063 showed PDE10A-specific accumulation; thus, ARG study with 
[3H]TAK-063 is a sensitive way to understand the localization of PDE10A protein (Harada et 
al., 2015). In vitro ARG study with a series of rat coronal brain sections demonstrated the high 
and significant accumulation of [3H]TAK-063 in the caudate—putamen, ventral pallidum, 
internal capsule, and substantia nigra, and low but significant accumulation in the 
hippocampus and amygdala (Figure 1). A phMRI study measuring cerebral BOLD signal 
responses produced by TAK-063 alone demonstrated that TAK-063 at 0.3 mg/kg apparently 
activated those brain areas in anesthetized rats (Figure 1). These data suggest that TAK-063 
modulates activities of multiple brain regions through the inhibition of PDE10A and the 
resulting activation of neuronal circuits.  
We recently reported that TAK-063 improved recognition memory assessed by novel object 
recognition task and attention and impulsivity assessed by five-choice serial reaction time task 
in naive rats. In addition, we reported that TAK-063 attenuated phencyclidine (PCP)-induced 
spatial working memory deficits assessed by Y-maze test and MK-801–induced spatial 
working memory deficits assessed by the eight-arm radial maze task in rats. TAK-063 also 
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ameliorated disturbed executive function in subchronic PCP-treated rats assessed by 
attentional set-shifting task (Shiraishi et al., 2016). These cognitive functions may be 
associated with various brain regions including the frontal cortex and retrosplenial cortex. 
Moreover, the neuronal activity in those regions can be modified by ketamine (Littlewood et 
al., 2006a); thus, we decided to further characterize the modulatory effects of TAK-063 on the 
neuronal activity after ketamine challenge in various brain regions. 
The reduction of the ketamine-induced cortical activity by TAK-063 at about 30% PDE10A 
occupancy was observed in the EEG gamma power analysis in both awake rats and monkeys 
(Figures 2 and 3), suggesting that TAK-063 can indeed modulate cortical function at a similar 
occupancy (~30%) beyond species. We next tried to assess the modulation of neuronal 
activity in a whole brain by using phMRI. Under anesthesia, phMRI responses to drugs of 
interest can vary compared with the awake state (Luo et al., 2007). However, by using 
isoflurane anesthesia, we confirmed the preserved effect of TAK-063 on the ketamine-induced 
increase in cortical gamma power (Figure 4). Thus, we expected to detect phMRI signals 
associated with anti-ketamine effects of TAK-063 under the experimental conditions. 
TAK-063 at 0.3 mg/kg suppressed the ketamine-induced neuronal activation in the cortex and 
reversed the ketamine-induced deactivation in the brainstem, cerebellum, and hypothalamus 
(Figure 5). Within cortical areas, modulation of neuronal activity by TAK-063 0.3 mg/kg i.p. 
was observed in prefrontal and retrosplenial cortex (Figures 5). The prefrontal cortex is 
implicated in cognitive functions like attention, impulsivity, and executive function (Birrell 
and Brown, 2000, Maddux and Holland, 2011), and the retrosplenial cortex is, by interacting 
with the hippocampus, implicated in the recognition and working memory functions (Haijima 
and Ichitani, 2008, Cohen and Stackman, 2015). The improvement of cognitive function 
produced by TAK-063 (Shiraishi et al., 2016) may result from the modulation of neuronal 
activity of these brain regions, although further studies are needed to elucidate the relationship 
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between the brain activity and pro-cognitive effects produced by TAK-063. 
We also investigated the consequences of overdosing by comparing the effects of TAK-063 at 
0.3 and 3 mg/kg. Although, overall, TAK-063 at 0.3 and 3 mg/kg produced similar responses 
in both phMRI and EEG, some differences were found. Namely, TAK-063 at 3 mg/kg 
decreased the BOLD signal in the brainstem and cerebellum (Figure 1) and reduced EEG 
gamma power in resting states of awake rats (Figure 2). In addition, TAK-063 at 3 mg/kg did 
not reverse the ketamine-induced phMRI-BOLD signal changes in the brainstem, cerebellum, 
thalamus, and hypothalamic areas (Figure 5). Further studies are needed to elucidate the 
relationship between brain activity, efficacy and the unwanted side effects produced by 
overdosing. 
Different from TAK-063, MP-10 did not significantly reduce the ketamine-induced increase 
in gamma power in rats (Figure 2). In our previous study, TAK-063, but not MP-10, showed 
potent antipsychotic-like effects in methamphetamine-induced hyperactivity and prepulse 
inhibition deficits in rodents (Suzuki et al., 2016). We hypothesize that the excess activation 
of the direct pathway by MP-10 may be associated with its lack of efficacy in these paradigms. 
In fact, excess activation of the direct pathway by a dopamine D1 receptor agonist SKF82958 
canceled antipsychotic-like effects of a dopamine D2 receptor antagonist haloperidol in 
methamphetamine-induced hyperactivity in rats (Suzuki et al., 2016). TAK-063 has a faster 
off-rate than MP-10, and thus, shows higher sensitivity to binding inhibition by cyclic 
nucleotides. Cyclic AMP levels in the direct pathway of MSNs seemed to be higher than those 
in the indirect pathway of MSNs. Therefore, TAK-063 and MP-10 activated the indirect 
pathway to a similar extent, while MP-10 caused greater activation of the direct pathway than 
TAK-063 did (Suzuki et al., 2016). This difference in the neuronal activation pattern may 
relate to the observed differences in the reduction of the ketamine-induced increase in gamma 
power (Figure 2). 
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In summary, we demonstrated that TAK-063 at 0.3 mg/kg i.p. in rats and at 0.2 mg/kg i.v. in 
monkeys modified the activity of various brain regions beyond the localization of PDE10A 
protein. We have previously demonstrated that TAK-063 at 0.3 mg/kg p.o. produced 
antipsychotic effects and cognitive improvements in animal models of schizophrenia (Suzuki 
et al., 2015, Shiraishi et al., 2016, Suzuki et al., 2016). TAK-063 at the efficacious dosage 
may have the potential to modulate multiple brain circuits, including the corticostriatal circuit, 
via the specific binding to PDE10A, and can provide an opportunity to treat CNS disorders 
associated with dysfunction in multiple brain regions. Both EEG and phMRI are highly 
translational methods that can be performed in both animals and humans. The EEG and 
phMRI data we show here would be useful to bridge pre-clinical and clinical studies. 
TAK-063 is currently in clinical development in patients with schizophrenia 
(ClinicalTrials.gov Identifiers: NCT02477020). 
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Figure captions 
Figure 1 Comparison between [3H]TAK-063 accumulation in autoradiography and 
phMRI-BOLD signals induced by TAK-063. A. Typical autoradiogram data showing the high 
[3H]TAK-063 radioactivity in brain areas including caudate—putamen (CPu), ventral 
pallidum (VP), internal capsule (ic), and substantia nigra (SN). Numbers indicate the posterior 
(-) and anterior (+) stereotaxic position (mm) from the bregma. B. Regions of interest (ROI) 
analysis with or without MP-10. MP-10 significantly decreased the PSL values in the CPu, VP, 
hippocampus (Hipp), ic, amygdala (Amy), and SN. TAK-063 elevated cAMP (C) and cGMP 
(D) levels in the rat striatum 30 min after i.p administration. E. TAK-063 suppressed the 
MK-801-induced (0.3 mg/kg s.c.) hyperactivity in rats. F. Coronal section statistical 
parametric mapping (SPM) figures of the phMRI-BOLD with TAK-063 at 0.3 mg/kg. 
TAK-063 at 0.3 mg/kg produced prominent activation of the CPu and Amy, and some 
negative changes in the frontal cortex (Fcx) including medial part. G. Coronal section SPM 
figures of the phMRI-BOLD with TAK-063 at 3 mg/kg. TAK-063 at 3 mg/kg produced 
localized and bilateral increases in BOLD signals in the CPu and Amy and prominent 
negative BOLD signals in the brainstem (Bs) and cerebellum (Cb). H. Sagittal section SPM 
figures of the phMRI-BOLD with TAK-063. TAK-063 at 0.3 and 3 mg/kg produced 
significant increases in BOLD signals in the CPu and SN corresponding with the high specific 
binding of [3H]TAK-063 observed in ARG with rat sagittal brain sections. Data are presented 
as means+SEMs. n=4 for each group in autoradiography study, n=7–9 for measurement of 
cyclic nucleotide study, n=4–6 for locomotor study, n=8 for TAK-063 0.3 mg/kg, n=10 for 
TAK-063 3 mg/kg in phMRI study. * P≤0.05 by Aspin-Welch’s t-test, # P≤0.05 versus vehicle 
by Williams’ test. § P≤0.05 versus vehicle + MK-801 group by Shirley–Williams test. ARG, 
autoradiography; BOLD, blood-oxygen-level dependent; cAMP, cyclic adenosine 
monophosphate; cGMP, cyclic guanosine monophosphate; Cont, control; i.p., intraperitoneal; 
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MB, midbrain; PFC, prefrontal cortex; phMRI, pharmacological magnetic resonance imaging; 
PSL; photostimulated luminescence; s.c., subcutaneous, SEMs, standard error of the means; 
Veh: vehicle. 
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Figure 2 Effects of TAK-063 and MP-10 on EEG gamma power analyzed by Fast Fourier 
Transformations (FFT) in awake rats with or without ketamine challenge. A. Experimental 
scheme is shown on top of the figure. TAK-063 reduced the gamma power in the resting 
states. TAK-063 also reduced the gamma power in the ketamine-induced activated states. The 
timing of ketamine administration is indicated as 0 min. B. TAK-063 at 3 mg/kg significantly 
reduced the AUC of the gamma power in resting states. C. Ketamine significantly increased 
the AUC of gamma power, and TAK-063 significantly reduced the ketamine-induced increase 
in AUC of the gamma power. D. Experimental scheme is shown on top of the figure. MP-10 
reduced the gamma power in the resting states. The timing of ketamine administration is 
indicated as 0 min. E. MP-10 at 30 mg/kg significantly reduced the AUC of the gamma power 
in resting states. F. Ketamine significantly increased the AUC of gamma power; however, 
MP-10 did not significantly reduce the ketamine-induced increase in AUC of the gamma 
power. Data are presented as means+SEMs (n=4 for each group). *P≤0.05 by Aspin-Welch’s 
t-test, #P≤0.05 by Williams’ test, AUC, area under the curve; EEG, electroencephalogram; Ket 
-, without ketamine; Ket +, with ketamine; MP, MP-10; p.o., oral; s.c., subcutaneous; SEMs, 
standard error of the means; TAK, TAK-063; Veh, vehicle. 
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Figure 3 Effects of TAK-063 on EEG gamma power analyzed by Fast Fourier 
Transformations (FFT) in awake monkeys with or without ketamine challenge. A. 
Experimental scheme is shown on top of the figure. TAK-063 did not modify the gamma 
power in the resting states, while it reduced the gamma power in the ketamine-induced 
activated states. The timing of ketamine administration is indicated as 0 min. B. TAK-063 did 
not affect the AUC of the gamma power in resting states. C. Ketamine significantly increased 
the AUC of the gamma power, and TAK-063 significantly suppresses the ketamine-induced 
increase in AUC of the gamma power. Data are presented as means+SEMs (n=6 for each 
group). *P≤0.05 by Aspin-Welch’s t-test, #P≤0.05 by Williams’ test, AUC, area under the 
curve; EEG, electroencephalogram; i.v., intravenous; i.m., intramuscular; Ket -, without 
ketamine; Ket +, with ketamine; SEMs, standard error of the means; TAK, TAK-063; Veh, 
vehicle. 
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Figure 4 Effects of TAK-063 on EEG gamma power analyzed by Fast Fourier 
Transformations (FFT) in isoflurane anesthetized rats with or without ketamine challenge. A. 
Experimental scheme is shown on top of the figure. TAK-063 did not modify the EEG gamma 
power in the resting states, while it reduced the ketamine-induced increase in EEG gamma 
power under isoflurane anesthetized conditions. The timing of ketamine administration is 
indicated as 0 min. B. TAK-063 alone did not affect the AUC of gamma power. C. The 
ketamine-induced increase in gamma power was significantly reduced by TAK-063. Data are 
presented as means+SEMs. n=4 for vehicle without ketamine, n=6 for vehicle + ketamine and 
TAK-063 3 mg/kg + ketamine, n=5 for TAK-063 0.3 mg/kg + ketamine. *P≤0.05 by 
Aspin-Welch’s t-test, #P≤0.05 by Williams’ test, AUC, area under the curve; EEG, 
electroencephalogram; i.p, intraperitoneal; Ket -, without ketamine; Ket +, with ketamine; s.c., 
subcutaneous; SEMs, standard error of the means; TAK, TAK-063; Veh, vehicle. 
 
  
33 
 
Figure 5 Effects of TAK-063 on the ketamine-induced changes in phMRI-BOLD signal under 
isoflurane anesthetized conditions shown by statistical parametric maps (SPM) figures. A–C. 
Significant changes in the phMRI-BOLD signal produced by ketamine with or without 
TAK-063 are depicted on a rat brain atlas (Paxinos and Watson, 1997). Red letters indicate 
activation and blue letters indicate deactivation of the phMRI-BOLD signals. D. Ketamine 
challenge produced a widespread activation in the cortex, hippocampus, and 
striatum/amygdaloid complex; negative BOLD-contrast changes were observed in the 
brainstem, cerebellum, and hypothalamus. E. TAK-063 at 0.3 mg/kg suppressed the twoin the 
brainstem, cerebellum, and hypothalamus. In addition, TAK-063-induced increase in 
activation was observed in the thalamic and subthalamic areas, and the striatum. F. TAK-063 
at 3 mg/kg produced a stronger suppression of the cortical activation, and a more robust and 
localized activation of the striatum/amygdaloid complex. n=8 for vehicle + ketamine, n=8 for 
TAK-063 0.3 mg/kg + ketamine, n=10 for TAK-063 3 mg/kg + ketamine. BOLD, blood 
oxygenation level dependent; phMRI, pharmacological magnetic resonance imaging. 
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Highlights 
 [3H]TAK-063 highly accumulated in the striatum and substantia nigra. 
 TAK-063 modified the phMRI-BOLD signal beyond the localization of PDE10A in rats. 
 TAK-063 suppressed the ketamine-induced cortical EEG activation in rats and monkeys. 
 TAK-063 modulated ketamine-induced BOLD changes in various brain regions in rats.  
 
 
